In 2010, the global blood disorders market was estimated to be worth $39.4 billion, representing a CAGR of 6.9% between 2002 and 2010. By 2017, the global blood disorders market is expected to reach $50.9 billion, growing at a CAGR of 3.7% between 2010 and 2017. The major reason for this reduced growth rate is the expected decline in the annual cost of treating blood disorders after 2010.
The global blood disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes most of the top selling blockbuster drugs in the anemia, thrombosis, hemophilia, neutropenia and Alexander's disease markets. The major drugs that are set to lose patent protection between 2010 and 2017 include Kogenate FS in the UK and Germany (2009), NovoSeven (2010), ReFacto (2010), BeneFIX (2011) and Kogenate FS in the US (2014), Plavix (2011), Lovenox (2012), Neupogen (2013), Epogen/Procrit (2013), Aranesp (2014) and Neulasta (2015).
All these drugs together account for approximately $32 billion of revenues in the global blood disorders market.
While the current blood disorders pipeline does offer some promising products, the revenues generated from these products are not expected to completely offset the revenue lost due to patent expiries. Thus, in the future, the overall growth of the global blood disorders market is expected to decline.
The Blood Disorders Therapeutics Market is Concentrated, with Amgen, Bristol-Myers Squibb and Sanofi Controlling Approximately 61% of the Market
The current global blood disorders market is significantly consolidated as the top three players in the market, Amgen, Bristol-Myers Squibb (BMS) and Sanofi, control approximately 61% of the market. Amgen is the current market leader with its blockbuster products, Neulasta (pegfilgrastim), Epogen (epoetin alpha), Aranesp (darbepoetin) and Neupogen (filgrastim) controlling 31.3% of the total blood disorders market in 2010. BMS follows with a 16.9% market share, primarily due to its top selling thrombosis product, Plavix. Sanofi's third position is attributed to the sales of Plavix (clopidogrel) and Lovenox (enoxaparin), which also have a significant presence in the branded blood disorders market for the treatment of thrombosis, with a share of 12.4% of the global blood disorders therapeutics market. Baxter and Centocor Ortho Biotech Inc. are the fourth and the fifth largest players, primarily due to Advate (antihemophilic factor), Recombinate (factor VIII) and Procrit (epoetin alpha), respectively. The companies control 5.3% and 4.1% of the total blood disorders market, respectively.
The Blood Disorders Therapeutics Pipeline is Dominated by Early-Stage Development Products
The current blood disorders market scenario demands substantial output from the research and development (R&D) departments of pharmaceutical companies. With a series of patent expiries planned in the next seven years, disease indications such as thrombosis, anemia, hemophilia A, hemophilia B and Alexander's disease are set to lose billions of dollars of revenue from the market as a result.
The current pharmaceutical pipeline for blood disorders does contain some promising drugs. However, the drugs are not expected to completely replace the revenue losses experienced due to the patent expiries of the current blockbuster drugs, such as Plavix, Neulasta, Epogen, Aranesp, Kogenate FS (antihemophilic factor), NovoSeven (coagulation factor VIIa) and BeneFIX (coagulation factor IX), among others.
The current blood disorders pipeline contains 154 projects across eight major indications. Hemophilia, currently accounting for more than 36% of the total blood disorders market, is the key therapy area of focus in the current pipeline. Anemia is the second largest indication, with 25% of pipeline molecules, while thrombosis is third, with 23% of the global blood disorders pipeline molecules.
About 3% of the total projects for blood disorders have been NDA Filed. Molecules at the phase III stage account for 14%, while phase II and phase I molecules account for 23% each. This is followed by molecules at the preclinical stage, which account for 34%. 3% of the blood disorders pipeline molecules are currently at the discovery stage.
Many patent expiries during the forecast period may be the reason for the decline of the blood disorders therapeutics market from 2010 to 2017. This loss is expected to be off-set by late-stage pipeline molecules during the forecast period.
This report provides in-depth analysis of drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
The scope of this report includes -
- Annualized market data for the blood disorders market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including anemia, thrombosis, neutropenia, hemophilia A, hemophilia B, hemophilia C, von Willebrand's disease and Alexander disease.
- Analysis of the blood disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the blood disorders market, including market size, annual cost of treatment and treatment usage pattern.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Amgen, Bristol-Myers Squibb, Sanofi-Aventis, Baxter and Centocor Ortho Biotech Inc.
- Key M&A activities, licensing agreements, that have taken place from 2004 to 2011 in the global blood disorders market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Click for Report details:Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth